Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $1.13 in the prior trading day, Lyell Immunopharma Inc (NASDAQ: LYEL) closed at $1.08, down -4.42%. In other words, the price has decreased by -$4.42 from its previous closing price. On the day, 0.55 million shares were traded. LYEL stock price reached its highest trading level at $1.1896 during the session, while it also had its lowest trading level at $1.06.
Ratios:
Our goal is to gain a better understanding of LYEL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.19 and its Current Ratio is at 16.19. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on June 27, 2024, Downgraded its rating to Neutral and sets its target price to $1 from $6 previously.
On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $15 to $5.
Morgan Stanley Downgraded its Overweight to Equal-Weight on November 14, 2022, whereas the target price for the stock was revised from $15 to $7.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 276483264 and an Enterprise Value of -154414640. For the stock, the TTM Price-to-Sale (P/S) ratio is 5529.60 while its Price-to-Book (P/B) ratio in mrq is 0.49. Its current Enterprise Value per Revenue stands at -2859.53 whereas that against EBITDA is 0.755.
Stock Price History:
Over the past 52 weeks, LYEL has reached a high of $3.26, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -20.75%, while the 200-Day Moving Average is calculated to be -45.07%.
Shares Statistics:
The stock has traded on average 665.39K shares per day over the past 3-months and 488740 shares per day over the last 10 days, according to various share statistics. A total of 253.96M shares are outstanding, with a floating share count of 114.05M. Insiders hold about 55.45% of the company’s shares, while institutions hold 26.32% stake in the company. Shares short for LYEL as of 1726185600 were 13222068 with a Short Ratio of 19.87, compared to 1723680000 on 15032905. Therefore, it implies a Short% of Shares Outstanding of 13222068 and a Short% of Float of 7.33.
